Lacosamide Krka (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes hyper‑excitable neuronal membranes, limits repetitive firing, and thereby reduces the likelihood of seizure generation without significantly affecting normal rapid sodium channel activity.

The dosage of Lacosamide Krka is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. The prescriber determines the starting dose and any titration schedule according to approved labeling and clinical judgment.

Safety data for Lacosamide Krka in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Lacosamide Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation of sodium channels, which may result in a different side‑effect profile and fewer drug‑interaction concerns. It is often chosen when patients need additional seizure control without the enzyme‑inducing properties of some alternatives.

Lacosamide Krka should be stored at temperatures below 25 °C in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight. Do not store in a bathroom or near a kitchen sink where humidity is high.

Lacosamide Krka is administered orally. The tablet should be swallowed whole with a glass of water and may be taken with or without food, according to the prescriber’s instructions. Consistency in administration timing helps maintain stable drug levels.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which may lead to arrhythmias, as well as rare but severe skin reactions (e.g., Stevens‑Johnson syndrome) and the emergence of suicidal thoughts or behavior. Patients should be monitored closely for these events.

Lacosamide Krka should be avoided in individuals with known hypersensitivity to lacosamide or any of its excipients, and in patients with severe cardiac conduction disorders (e.g., advanced atrioventricular block) unless under specialist supervision. Caution is also advised for patients with significant renal or hepatic impairment.